Regeneron, Sanofi Say Japan Grants Marketing Authorization for Dupixent

, MT Newswires -  3:22 AM ET 3/28/2025 Company News

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print

03:22 AM EDT, 03/28/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Friday their Dupixent, or dupilumab, drug was approved in Japan for the treatment of chronic obstructive pulmonary disease, or COPD, in adults.

COPD is a chronic respiratory disease that damages the lungs and causes lung function to decline.

The Japanese Ministry of Health, Labour and Welfare granted marketing and manufacturing authorization for the drug based on data from a phase 3 trial. The study showed the product significantly reduced exacerbations and improved lung function compared with placebo, the companies said.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

© 1999-2025 Midnight Trader, Inc. All rights reserved.

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print
close
Please enter a valid e-mail address
Please enter a valid e-mail address
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.
close

Your e-mail has been sent.